To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Minimum Information about… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization

Journal article
Authors A. Fuchs
M. Gliwinski
N. Grageda
R. Spiering
A. K. Abbas
S. Appel
R. Bacchetta
M. Battaglia
D. Berglund
B. Blazar
J. A. Bluestone
M. Bornhauser
A. ten Brinke
T. M. Brusko
N. Cools
M. C. Cuturi
E. Geissler
N. Giannoukakis
K. Golab
D. A. Hafler
S. M. van Ham
J. Hester
K. Hippen
M. Di Ianni
N. Ilic
J. Isaacs
F. Issa
D. Iwaszkiewicz-Grzes
E. Jaeckel
I. Joosten
D. Klatzmann
H. Koenen
C. van Kooten
Olle Korsgren
K. Kretschmer
M. Levings
N. M. Marek-Trzonkowska
M. Martinez-Llordella
D. Miljkovic
K. H. G. Mills
J. P. Miranda
C. A. Piccirillo
A. L. Putnam
T. Ritter
M. G. Roncarolo
S. Sakaguchi
S. Sanchez-Ramon
B. Sawitzki
L. Sofronic-Milosavljevic
M. Sykes
Q. Z. Tang
M. Vives-Pi
H. Waldmann
P. Witkowski
K. J. Wood
S. Gregori
C. M. U. Hilkens
G. Lombardi
P. Lord
E. M. Martinez-Caceres
P. Trzonkowski
Published in Frontiers in Immunology
Volume 8
ISSN 1664-3224
Publication year 2018
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Language en
Keywords minimum information model, T regulatory cells, immunotherapy, good manufacturing practice, cell, chimeric antigen receptor, versus-host-disease, adoptive transfer, in-vitro, transplantation, blood, expansion, allograft, tolerance, therapies, Immunology
Subject categories Microbiology and immunology


Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?